The Trump administration has introduced legislation outlining plans for deep cuts to Medicaid, possibly impacting millions of ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

It is vital for biotech companies to run the right clinical trial and not cut costs, the Sanofi executive said.